INTRODUCTION
The pathogenesis of hyperbilirubinemic encephalopathy remains incompletely understood but central to its development is the passage of bilirubin across the blood-brain barrier into the central nervous system (CNS). 1 Studies suggest that bilirubin is a substrate for Pglycoprotein (Pgp) 2 -4 and that blood-brain barrier Pgp may play a role in limiting the passage of bilirubin into the CNS. 2 Pgp, an ATPdependent integral plasma membrane efflux pump is (1) expressed in abundance on the luminal aspect of adult brain capillary endothelial cells and astrocytes of the blood-brain barrier 2,3,5 -11 and (2) limits the brain influx and CNS retention of a wide variety of unrelated lipophilic compounds. 6, 10 In addition, Pgp is expressed on brush border epithelial cells of the intestinal mucosa where it limits the absorption and oral bioavailability of numerous lipophilic drugs. 12 -14 Thus, intestinal Pgp may also play a role in modulating the enterohepatic circulation of bilirubin, a phenomenon that accounts for up to 50% of the newborn hepatic bilirubin load. This review will summarize the current evidence characterizing unconjugated bilirubin as a substrate for Pgp and recent data on the ontogeny of Pgp in the CNS and gastrointestinal (GI) tract, issues critical to deciphering the potential role of Pgp in the disposition of bilirubin in the neonate.
P-GLYCOPROTEIN
Pgp is a member of the ATP-binding cassette superfamily of transport proteins that utilize ATP to translocate a wide range of substrates across biologic membranes. 10 There is now considerable evidence that Pgp extracts its' substrates directly out of the plasma membrane before they get into the cell. This model referred to as the ''vacuum cleaner'' hypothesis has gained increased acceptance among investigators and provides an intriguing framework to understand the function of Pgp. 10 Pgp is encoded for by a family of genes referred to as the multidrug resistance (MDR) genes (MDR1 and MDR2 in humans; mdr1a, mdr1b and mdr2 in murine species). 10 The intron-exon structure of the human MDR1 and mouse mdr1a genes are virtually identical. 10 This gene encodes the Pgp isoform expressed in brain capillary endothelial cells and astrocytes of the blood-brain barrier and brush border epithelial cells of the intestinal mucosa. 10 In this article, Pgp refers only to the human MDR1 and/or mouse mdr1a isoforms.
BILIRUBIN AND P-GLYCOPROTEIN
One of the distinctive features of Pgp is its broad substrate specificity. 5, 6, 10, 15 Recent studies by others and us suggest that unconjugated bilirubin is a substrate for Pgp. Such evidence includes (1) the ability of unconjugated bilirubin to inhibit the photoaffinity labeling of Pgp by a photoaffinity probe specific for Pgp 3 and (2) the limited uptake of [ 3 H]bilirubin by human multidrug resistant variant cells as compared with parent cells, which do not express the MDR1 gene. 4 Unconjugated bilirubin exhibits many features characteristic of Pgp substrates. 15 These include its hydrophobic nature and distinct structural elements required for interaction with Pgp recently reported by Seelig, 15 specifically electron donor groups with a spatial separation of approximately 2.5±0.3 Å. Bilirubin P -glycoprotein ( Pgp ) , an ATP -dependent plasma membrane efflux pump, is expressed in abundance on the luminal aspect of brain capillary endothelial cells and astrocytes of the blood -brain barrier where it limits the passage of a variety of lipophilic substrates into the central nervous system. This review summarizes current evidence characterizing ( 1 ) unconjugated bilirubin as a potential substrate for Pgp and ( 2 ) the ontogeny of Pgp expression at the blood -brain barrier and apical brush border epithelium of the gastrointestinal tract, findings that may provide insights regarding the disposition of bilirubin in immature subjects. 
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demonstrates several such donor groups (Anna Seelig, PhD, personal communication).
BRAIN BILIRUBIN CONTENT IN MDR1A NULL MUTANT MICE
Deciphering the physiologic role of Pgp has been greatly enhanced by using molecular genetic techniques (transgenesis) to create Pgpdeficient null mutant lines. 6 We confirmed that mdr1a Pgp is expressed in abundance in wild-type mouse brain capillary endothelial cells but absent in mdr1a[ À / À ] null mutant Pgpdeficient mouse brain microvessels as determined on Western immunoblots 2 ( Figure 1 ). Moreover, we observed that brain bilirubin content was significantly higher (approximately two-fold greater) in mdr1a[ À / À ] Pgp-deficient mice as compared with wild-type mice of the same mixed genetic background 10 minutes after a 50 mg/kg intravenous bilirubin load ( Figure 2 ). 2 Brain bilirubin content declined in both groups 60 minutes following completion of the bilirubin infusion but remained significantly higher in mdr1a[ À / À ] mice than in control animals ( Figure  2 ). 2 Brain bilirubin clearance (t 1 / 2 $55 minutes) and serum bilirubin levels at each time point did not differ between groups. 2 These data show that mdr1a[ À / À ] Pgp-deficient mice have higher brain bilirubin content compared with Pgp-sufficient controls following an intravenous bilirubin load supporting the assertion that bilirubin is a substrate for Pgp. Moreover, the difference in brain bilirubin content between mdr1a[ À / À ] null mutant and control animals was noted despite similar serum bilirubin levels 2 and rates of brain bilirubin clearance across study groups. The latter suggests that Pgp did not alter CNS bilirubin retention once bilirubin crossed the blood-brain barrier, but that the higher brain bilirubin content of mdr1a[ À / À ] mice was mediated by enhanced brain bilirubin influx. This finding is consistent with the hydrophobic vacuum cleaner model proposed by Gottesman and Patan 10 in which Pgp intercepts its substrates within the plasma membrane and pumps them into the extracellular space before they enter the cytoplasm. Our results support the concept that blood-brain barrier Pgp expression plays a role in protecting the CNS against bilirubin neurotoxicity by reducing brain bilirubin influx.
BILIRUBIN TRANSPORT BY CACO-2 CELLS EXPRESSING PGP
Caco-2 cells, derived from a human colorectal carcinoma cell line, overexpress Pgp on their apical membrane. 12 In vitro, Caco-2 cells differentiate into a monolayer that morphologically and functionally resembles small intestinal brush border columnar epithelium. Investigators have used Caco-2 cell monolayers to study the transport of Pgp substrates across the intestinal mucosa and have consistently demonstrated a net efflux of such compounds in a basal to apical direction. 12 We have initiated pilot studies of Pgp-mediated bilirubin efflux across intestinal epithelium using the human Caco-2 cell in vitro monolayer model. Specifically, we have assessed the basal to apical transport of tritiated ( [ 3 H] ) bilirubin by Caco-2 cells in the presence or absence of verapamil, a well-characterized Pgp inhibitor. 13 Transport experiments were performed using biosynthetic 
ONTOGENY OF P-GLYCOPROTEIN IN THE CENTRAL NERVOUS SYSTEM AND GASTROINTESTINAL TRACT
Studies on Pgp and bilirubin were performed in adult animals and tissues. Critical to our understanding of the potential role of Pgp in modulating bilirubin disposition in neonates is the characterization of Pgp expression during perinatal and postnatal development. We have observed marked developmental increases in Pgp expression in both the CNS 7 and gastrointestinal tract 14 of FVB mice ( Figure 4 ). Thus, in murine species it appears that brain microvessel and gastrointestinal tract Pgp expression undergo marked postnatal modulation and that neonatal Pgp expression in these tissues is quite limited.
Similarly, we have observed that Pgp is expressed in a developmental, regionally specific, and cell-specific fashion in postmortem brain tissue sections of infants born at 23 to 42 weeks' gestation. 8 More specifically, Pgp was expressed in capillary endothelial cells, astrocytes, and choroid plexus epithelium as early as 23 weeks' gestation and the intensity of staining increased during gestation until term paralleling cellular maturation (i.e., earlier in hindbrain, later in forebrain). By term, Pgp expression was most intense in endothelial cells of small vessels and observed in choroid plexus epithelium, ependyma, astrocytes, and large pyramidal neurons in hindbrain, allocortex and neocortex. Pgp localization in adult brain (positive control) matched that of term brain tissue but was more intense 8 consistent with the overall pattern of brain maturation. Thus, as in the FVB mouse, 7 Pgp was detected in the human blood-brain barrier during fetal life and such expression was developmentally regulated. 8 Our data also confirm cell-and region-specific Pgp expression within the CNS, a phenomenon described by others in adult human brain 9 and observed by us in adult mice. 11 The latter murine study showed abundant Pgp expression in the cortex and cerebellum but only limited Pgp expression in the thalamus (including subthalamic nucleus and globus pallidus) and spinal cord. 11 Low levels of Pgp expression within these regions could theoretically increase their susceptibility to injury by neurotoxic Pgp substrates including bilirubin. It is of interest in this regard that the thalamus and spinal cord evidence enhanced susceptibility to bilirubin deposition and neuronal cell death in hyperbilirubinemic encephalopathy.
The factors that modulate the developmental pattern of Pgp expression in the CNS and gastrointestinal tract are unknown but may include both endogenous and exogenous regulators. The expression of mdr1a Pgp is modulated by corticosteroids and other hormones whose activity may change in the perinatal and postnatal periods. 16 In pilot studies we have observed that antenatal dexamethasone treatment increases brain Pgp expression two-fold in suckling pups. 17 Other modulators of Pgp expression include ligand activators such as chemosensitizers and cytotoxic compounds that the newborn may be exposed to during postnatal life. With respect to the GI tract, recent studies suggest that diet may be an important environmental factor affecting Pgp expression and activity. 18 In this regard, intestinal Pgp expression increases in pups while feeding breast milk, reaching adult levels at the time of weaning (i.e., 21 days of postnatal life). Breast milk contains various biologically active peptide growth factors (e.g., insulin-like growth factor I, epidermal growth factor) and hormones that are known to stimulate GI development as well as enhance Pgp expression and function in tumor cell lines in vitro. Whether these or other factors in breast milk modulate intestinal Pgp expression is unknown but the temporal relationship between the attainment of adult levels of intestinal Pgp and weaning suggests this issue warrants further study.
MODULATION OF PGP FUNCTION
The function of Pgp as an efflux pump can be modulated by (1) energy supply (ATP), (2) the presence of competitive inhibitors (chemosensitizers), and (3) Pgp polymorphisms. The absolute dependence of Pgp on ATP is evinced by observations that enhanced xenobiotic efflux by MDR cells is abolished by inhibitors of oxidative phosphorylation (e.g., sodium azide), by glucose deprivation, and by mutations of the Pgp ATP binding site, whereas efflux in parent cells is unaffected. Consistent with these findings are studies that show a marked impairment of blood-brain barrier Pgp-mediated drug efflux in the context of transient forebrain ischemia in rodents. In the context of our recent observation of Pgp limiting brain bilirubin influx, 2 the aforementioned studies would predict that brain asphyxia would impair Pgp-mediated bilirubin transport and enhance bilirubin influx into the CNS. Animal and clinical studies suggest that asphyxia may increase the risk for kernicterus. Whether the latter is mediated by impaired bloodbrain barrier Pgp function has not been addressed but is a hypothesis that merits further study.
The function of Pgp in limiting and/or reducing the intracellular concentrations of its substrates can also be modulated by a wide range of compounds termed chemosensitizers, Pgp inhibitors, or MDR-reversers. Chemosensitizers described to date include a wide variety of compounds, some of which may be used in neonates. This list includes, among others, antiarrthymics (e.g., propranolol), antibiotics (e.g., ceftriaxone, erythromycin, rifampin), antifungals (e.g., ketoconazole), calcium channel blockers (e.g., verapamil, nifedipine, diltiazem), hormones (e.g., dexamethasone, cortisol), and miscellaneous compounds (e.g., vitamin A). Most exert their effect by competitive inhibition. With respect to the interaction of bilirubin with Pgp at the blood-brain barrier, the aforementioned reversal agents would be expected to enhance brain bilirubin uptake and retention. 19 An analogous effect on the bilirubin-Pgp interaction at the intestinal mucosa may be predicted with the oral administration of Pgp inhibitors.
Pgp function is ultimately dependent on the level of Pgp expressed and any polymorphisms that might impact the efficacy of the protein product to recognize substrates and pump them out of cells. The level of Pgp expression as function of development was described previously. Whether allelic differences in individual human MDR1 gene sequences exist that modulate different expression levels during maturation is unknown. There exists, however, a subpopulation of CF-1 mice that are deficient in mdr1a Pgp, a naturally occurring equivalent of the transgenic mdr1a[ À / À ] null mutant. These mice result from a spontaneous recessive mutation in the mdr1a gene although the specific mutation has yet to be identified. Does a similar polymorphism, or polymorphisms exist in humans? Three articles reported several naturally occurring human MDR1 polymorphisms. 20 -22 At least two of these are associated with decreased MDR1 expression levels (25% to 50% of control level) and may result from mutations in either the promoter or coding regions. 20, 22 Homozygosity for the exon 26 [C3435T] polymorphism in the gastrointestinal tract is also associated with decreased Pgp activity in vivo 20 and noted in almost one quarter of the sample population (healthy male Caucasian volunteers; n=188). 20 In contrast, 6 to 7 million humans in Africa and South America have been treated with Mectizan (ivermectin), an antiparasitic Pgp substrate that is neurotoxic to CF-1 and mdr1a[ À / À ] Pgp-deficient mice, but without clinical evidence of neurotoxicity in humans. 21 These data suggest that (1) MDR1 Pgp expression is highly conserved in humans overall and (2) defining a subgroup of humans with complete absence of Pgp expression is unlikely. 21 Nevertheless, an understanding of MDR1 polymorphisms and relative Pgp deficiency states will impact the treatment of patients 20 with Pgp substrates and could possibly provide insights regarding variation in bilirubin disposition in neonates.
SUMMARY: PGP AND BILIRUBIN -A CAUTIONARY NOTE
There is a growing body of evidence that unconjugated bilirubin is a substrate for Pgp. This evidence includes the results on bilirubin transport studies in both in vivo (mdr1a[ À / À ] null mutant transgenic mice) and in vitro (Caco-2 cell monolayers) model systems of Pgp function. These data, however, are largely indirect and some observations suggest that bilirubin may be a weak or low affinity substrate for Pgp.
3 Nevertheless, the current evidence combined with (1) the strategic localization of Pgp at the bloodbrain barrier and apical brush border epithelium of the GI tract, (2) the marked developmental modulation of Pgp expression in these tissues, and (3) the ATP dependence of Pgp, may account for certain aspects of bilirubin handling and tissue disposition in neonates. Additional study will be necessary to substantiate and further characterize the relationship between unconjugated bilirubin and Pgp and to identify other possible ATP-binding cassette transport proteins for which unconjugated bilirubin may be a substrate.
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